FDA CRL - NorthStar Medical Radioisotopes, LLC

The Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to NorthStar Medical Radioisotopes, LLC, regarding its New Drug Application (NDA 202158) for the TechneGen Generator System for preparing Sodium Pertechnetate Tc99m Injection. The application, submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, cannot be approved in its current form due to several significant deficiencies across clinical, product quality microbiology, and chemistry, manufacturing, and controls (CMC) aspects.Clinically, the FDA identified multiple shortcomings in the product labeling, including user manuals, training materials, and the package insert. These issues, concerning instructions for preparation and safe use, hindered a complete safety evaluation of the TechneGen system. NorthStar is advised to revise these materials and conduct a human factors testing study to provide robust data supporting safe usage.From a microbiological perspective, the application lacked sufficient data to demonstrate sterility assurance and maintain microbial control throughout the product's in-use period. Specific concerns included the potential for microbial contamination, biofilm formation in tubing and valves, and risks associated with leaking connections. The cleaning protocol also required validation, and the final patient dosage form lacked confirmation of sterilization, necessitating integrity testing of sterilizing filters. Furthermore, process validation studies were deemed inadequate, with the FDA requesting justification for deviations from industry best practices regarding aseptic processing simulations.Chemistry, Manufacturing, and Controls (CMC) issues included the need for detailed descriptions and assurance of optimized flow rates in the commercial generator, submission of data for commercial batches, and comprehensive information on quality attributes for ABEC resin. NorthStar must address these points to ensure the safe and effective manufacturing of the TechneGen system. This comprehensive response outlines the necessary actions for NorthStar Medical Radioisotopes, LLC to resolve these deficiencies and resubmit their application for potential approval.